Parametric Portfolio Associates LLC reduced its stake in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 34.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 282,959 shares of the company’s stock after selling 150,036 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.12% of Endo International worth $1,166,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Meeder Asset Management Inc. grew its stake in shares of Endo International by 47.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock worth $156,000 after buying an additional 12,127 shares in the last quarter. Commonwealth Bank of Australia grew its stake in shares of Endo International by 41.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock worth $273,000 after buying an additional 19,500 shares in the last quarter. Hunter Associates Investment Management LLC grew its stake in shares of Endo International by 37.4% in the 2nd quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock worth $388,000 after buying an additional 25,625 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Endo International by 56.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 167,064 shares of the company’s stock worth $689,000 after buying an additional 60,234 shares in the last quarter. Finally, Systematic Financial Management LP grew its stake in shares of Endo International by 63.4% in the 2nd quarter. Systematic Financial Management LP now owns 193,380 shares of the company’s stock worth $797,000 after buying an additional 75,035 shares in the last quarter. Institutional investors own 95.71% of the company’s stock.
In related news, Director Roger H. Kimmel sold 25,000 shares of Endo International stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $4.09, for a total transaction of $102,250.00. Following the completion of the transaction, the director now directly owns 123,309 shares of the company’s stock, valued at approximately $504,333.81. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by insiders.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Endo International had a negative net margin of 19.98% and a negative return on equity of 129.30%. The firm had revenue of $699.71 million during the quarter, compared to analysts’ expectations of $694.60 million. During the same period in the previous year, the company earned $0.76 EPS. The firm’s revenue for the quarter was down 2.1% compared to the same quarter last year. On average, equities research analysts predict that Endo International PLC will post 2.17 earnings per share for the current fiscal year.
A number of brokerages have commented on ENDP. Royal Bank of Canada reissued a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research note on Thursday, August 8th. Mizuho reissued a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research note on Wednesday, August 7th. Citigroup cut shares of Endo International from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $19.00 to $5.00 in a research note on Monday, June 17th. BidaskClub cut shares of Endo International from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 18th. Finally, Morgan Stanley set a $2.00 price objective on shares of Endo International and gave the stock a “sell” rating in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $7.89.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: What does a hold rating mean?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.